Current guidelines and recommendations for anemia management in patient with CKD is recombinant human erythropoietin (rhEPO) and its analogs (called erythropoiesis-stimulating agents, ESAs), supplemented with intravenous iron administration [9]. This evidence concerns the gene EPO and chronic kidney disease.